Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, 169856, Singapore.
Duke-Nus Medical School, Singapore, 169857, Singapore.
Nat Commun. 2022 Mar 17;13(1):1441. doi: 10.1038/s41467-022-29122-w.
Immune evasion is key to cancer initiation and later at metastasis, but its dynamics at intermediate stages, where potential therapeutic interventions could be applied, is undefined. Here we show, using multi-dimensional analyses of resected tumours, their adjacent non-tumour tissues and peripheral blood, that extensive immune remodelling takes place in patients with stage I to III hepatocellular carcinoma (HCC). We demonstrate the depletion of anti-tumoural immune subsets and accumulation of immunosuppressive or exhausted subsets along with reduced tumour infiltration of CD8 T cells peaking at stage II tumours. Corresponding transcriptomic modification occur in the genes related to antigen presentation, immune responses, and chemotaxis. The progressive immune evasion is validated in a murine model of HCC. Our results show evidence of ongoing tumour-immune co-evolution during HCC progression and offer insights into potential interventions to reverse, prevent or limit the progression of the disease.
免疫逃避是癌症发生和转移的关键,但在潜在治疗干预可以应用的中间阶段,其动态情况尚不清楚。在这里,我们通过对切除的肿瘤、其相邻的非肿瘤组织和外周血进行多维分析,显示出在 I 期至 III 期肝细胞癌(HCC)患者中发生了广泛的免疫重塑。我们证明了抗肿瘤免疫亚群的耗竭和免疫抑制或耗竭亚群的积累,同时伴随着 CD8 T 细胞浸润肿瘤的减少,在 II 期肿瘤中达到峰值。与抗原呈递、免疫反应和趋化作用相关的基因也发生了相应的转录组修饰。在 HCC 的小鼠模型中验证了这种渐进性免疫逃避。我们的研究结果表明,在 HCC 进展过程中存在肿瘤-免疫协同进化的证据,并为逆转、预防或限制疾病进展提供了潜在干预措施的见解。